Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
<h4>Unlabelled</h4>Taliglucerase alfa is a beta-glucocerebrosidase enzyme replacement therapy approved in the United States, Israel, and other countries for treatment of Type 1 Gaucher disease in adults, and is the first approved plant cell--expressed recombinant protein. In this report,...
Main Authors: | Richat Abbas, Glen Park, Bharat Damle, Raul Chertkoff, Sari Alon |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0128986 |
Similar Items
-
Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease
by: Gupta P, et al.
Published: (2017-06-01) -
Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story.
by: Bonita Rup, et al.
Published: (2017-01-01) -
Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
by: Ari Zimran, et al.
Published: (2018-02-01) -
A physiologically based pharmacokinetic and pharmacodynamic model for paraoxon in rainbow trout /
by: Abbas, Richat R.
Published: (1994) -
Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.
by: You-Hai Xu, et al.
Published: (2010-05-01)